GSK announces regulatory submission for umeclidinium monotherapy in US

GlaxoSmithKline plc today announced the submission of a regulatory application in the US for the investigational once-daily medicine, umeclidinium bromide (UMEC), for patients with chronic obstructive pulmonary disease (COPD).
Source: GSK news - Category: Pharmaceuticals Source Type: news